Krsnaa Diagnostics Q3FY26 Results: Revenue ₹5,179 Cr (Standalone), ₹5,801 Cr (Consolidated)
Krsnaa Diagnostics reported standalone revenue of ₹5,179.29 crore and consolidated revenue of ₹5,801.70 crore for the nine months ended December 31, 2025. Profit before tax was ₹781.89 crore (standalone) and ₹786.66 crore (consolidated). The company is contesting a ₹513.86 crore tax demand related to past assessment years.
The disclosure of a significant tax demand, even with management's assertion of no material impact, warrants a medium impact due to the potential for future financial implications and ongoing litigation.
The financial results are largely in line with expectations, and while there's a tax dispute, the management believes it will not have a material impact, leading to a neutral sentiment.
Krsnaa Diagnostics Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results during a meeting held on February 05, 2026.
For the nine months ended December 31, 2025, the company reported standalone revenue from operations of ₹5,179.29 crore and consolidated revenue from operations of ₹5,801.70 crore. Standalone profit before tax stood at ₹781.89 crore, while consolidated profit before tax was ₹786.66 crore.
The company also disclosed details regarding income tax assessments for assessment years 2017-18 and 2020-21 to 2023-24. The Income Tax authorities have made additions on account of undisclosed income and disallowance of certain deductions, resulting in a demand order of ₹513.86 crore. Krsnaa Diagnostics has filed appeals against these orders and has paid ₹39.27 crore (standalone) and ₹102.77 million (consolidated) under protest. The company also received show cause notices for AY 2018-19 and AY 2019-20, for which it has submitted preliminary information. Management believes these matters will not have a material impact on the financial statements.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.